Guillermo F Sanz

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3720808/guillermo-f-sanz-publications-by-year.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60 278 22,712 147 h-index g-index citations papers 5.69 25,779 5.2 294 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
278	Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria <i>Leukemia Research</i> , 2022 , 116, 106836	2.7	O
277	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	2
276	Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?. <i>Transplant Infectious Disease</i> , 2021 , 23, e13602	2.7	4
275	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1223-1233	2.2	25
274	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. <i>Blood</i> , 2021 , 138, 1429-1440	2.2	5
273	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2826-2833	4.4	1
272	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS. <i>Leukemia</i> , 2021 , 35, 835-849	10.7	20
271	Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2021 , 106, 114-125	3.8	1
270	Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question. <i>Bone Marrow Transplantation</i> , 2021 , 56, 769-778	4.4	6
269	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. <i>Leukemia</i> , 2021 , 35, 1745-1750	10.7	4
268	Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. <i>Lancet Haematology,the</i> , 2021 , 8, e135-e148	14.6	18
267	Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 261.e1-261.e7		
266	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. <i>British Journal of Haematology</i> , 2021 , 194, 708-717	4.5	1
265	A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS. <i>Blood Advances</i> , 2021 , 5, 3066-3075	7.8	О
264	Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes <i>Leukemia and Lymphoma</i> , 2021 , 1-5	1.9	3
263	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. <i>Leukemia Research</i> , 2020 , 99, 106472	2.7	2
262	Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2261-2269	4.4	2

(2019-2020)

261	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2147-2159	4.4	11
2 60	Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group. <i>British Journal of Haematology</i> , 2020 , 191, 405-417	4.5	3
259	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. <i>Leukemia</i> , 2020 , 34, 2441-2450	10.7	6
258	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection</i> , 2020 , 80, 333-341	18.9	6
257	Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. <i>Scientific Reports</i> , 2020 , 10, 5904	4.9	2
256	Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. <i>Haematologica</i> , 2020 , 105, 2516-2523	6.6	3
255	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020 , 34, 128-137	10.7	17
254	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 188, 605-622	4.5	14
253	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 358-366	4.7	20
252	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. <i>Nature Medicine</i> , 2020 , 26, 1549-1556	50.5	118
251	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. <i>Haematologica</i> , 2020 , 105, 632-639	6.6	16
250	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020 , 55, 431-440	4.4	6
249	Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. <i>Haematologica</i> , 2020 , 105, 640-651	6.6	17
248	Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 83-87	4.7	1
247	Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1818-1824	4.7	17
246	Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. <i>Annals of Hematology</i> , 2019 , 98, 2081-2088	3	13
245	Comparison of transfusion requirements in adult patients undergoing Haploidentical or single-unit umbilical cord blood stem cell transplantation. <i>European Journal of Haematology</i> , 2019 , 103, 172-177	3.8	3
244	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP FBMT. Bone Marrow Transplantation. 2019, 54, 1987-1994	4.4	15

243	RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib. <i>Acta Haematologica</i> , 2019 , 142, 92-97	2.7	4
242	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019 , 37, 367-374	2.2	66
241	Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation. <i>Transfusion and Apheresis Science</i> , 2019 , 58, 185-186	2.4	
240	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019 , 78, 393-401	18.9	9
239	Immunohaematological events related to changes in haematic and seric ABO group in patients undergoing haematopoietic stem cell transplantation with major ABO mismatch. <i>Transfusion Medicine</i> , 2019 , 29, 136-137	1.3	1
238	Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2019 , 60, 142-150	1.9	22
237	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019 , 21, e13158	2.7	9
236	Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2019 , 98, 2151-2162	3	2
235	In MDS, is higher risk higher reward?. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 381-390	3.1	1
234	Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS?. <i>Blood Advances</i> , 2019 , 3, 3454-3460	7.8	2
233	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1894-1903	11.6	25
232	Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. Journal of Molecular Diagnostics, 2019 , 21, 228-240	5.1	15
231	Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. <i>Mycoses</i> , 2019 , 62, 418-427	5.2	2
230	Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen. <i>European Journal of Haematology</i> , 2019 , 102, 331-340	3.8	4
229	Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries. <i>British Journal of Haematology</i> , 2018 , 181, 350	-3 155 9	7
228	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. <i>Leukemia Research</i> , 2018 , 67, 21-26	2.7	3
227	Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. <i>Leukemia</i> , 2018 , 32, 1380-1392	10.7	37
226	Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1463-1470	4.7	22

(2017-2018)

225	Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study. <i>Transfusion Medicine and Hemotherapy</i> , 2018 , 45, 162-166	4.2	6
224	The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS. <i>Leukemia Research</i> , 2018 , 70, 34-36	2.7	7
223	MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination. <i>Blood</i> , 2018 , 132, 4357-435	72.2	1
222	Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2018 , 97, 161-167	3	12
221	Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. <i>HemaSphere</i> , 2018 , 2, e150	0.3	48
220	The modular network structure of the mutational landscape of Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2018 , 13, e0202926	3.7	3
219	Current management of patients with chronic myelomonocytic leukemia. <i>Current Opinion in Oncology</i> , 2018 , 30, 409-417	4.2	5
218	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. <i>Leukemia Research</i> , 2018 , 73, 51-57	2.7	13
217	Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes. <i>Blood Advances</i> , 2018 , 2, 2079-2089	7.8	11
216	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018 , 20, e12926	2.7	16
215	Isohaemagglutinin production after minor ABO incompatible umbilical cord blood transplantation. <i>Transfusion Medicine</i> , 2017 , 27, 147-149	1.3	3
214	Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. <i>Blood</i> , 2017 , 129, 525-532	2.2	6
213	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 1753-1762	2.2	189
212	Assessment of late cardiomyopathy by magnetic resonance imaging in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and idarubicin. <i>Annals of Hematology</i> , 2017 , 96, 1077-1084	3	7
211	Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. <i>American Journal of Hematology</i> , 2017 , 92, E534-E541	7.1	2
210	Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). <i>American Journal of Hematology</i> , 2017 ,	7.1	8
209	A Lot to Learn about Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 713-714	4.7	3
208	Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. <i>Journal of Internal Medicine</i> , 2017 , 281, 284-299	10.8	17

207	Should Molecular Genetics Guide the Decision for Allogeneic Transplant? - Con. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, S83-S84	2	
206	Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. <i>British Journal of Haematology</i> , 2017 , 179, 790-801	4.5	6
205	Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. <i>Oncotarget</i> , 2017 , 8, 106948-106961	3.3	29
204	Reply to M.A. Lichtman. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1376-1377	2.2	
203	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1591-1597	2.2	55
202	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 6478-6486	12.9	21
201	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. <i>Leukemia Research</i> , 2017 , 63, 85-89	2.7	5
200	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 128	22.4	14
199	Infections of the Central Nervous System after Unrelated Donor Umbilical Cord Blood Transplantation or Human Leukocyte Antigen-Matched Sibling Transplantation. <i>Biology of Blood</i> and Marrow Transplantation, 2017 , 23, 134-139	4.7	21
198	Excess mortality in the myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2017 , 92, 149-154	7.1	15
197	Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1686-1693	1.9	12
196	ABO incompatibility does not influence transfusion requirements in patients undergoing single-unit umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2017 , 52, 394-399	4.4	7
195	Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2017 , 7, 630	7	9
194	Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. <i>Clinical Case Reports (discontinued)</i> , 2017 , 5, 1887-1890	0.7	6
193	Single umbilical cord blood with or without CD34 cells from a third-party donor in adults with leukemia. <i>Blood Advances</i> , 2017 , 1, 1047-1055	7.8	6
192	Single or Double Cord Blood Unit for Transplant: What Have We Learned? 2017 , 37-45		
191	Umbilical cord blood transplantation in adults with advanced hodgkinN disease: high incidence of post-transplant lymphoproliferative disease. <i>European Journal of Haematology</i> , 2016 , 96, 128-35	3.8	17
190	Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Modern Pathology, 2016, 29, 1541-1551	9.8	11

189	Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3284-92	2.2	18
188	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. <i>Blood</i> , 2016 , 128, 2096-2097	2.2	25
187	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. <i>Genes Chromosomes and Cancer</i> , 2016 , 55, 322-7	5	6
186	Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authorsNeply. <i>Leukemia</i> , 2016 , 30, 740-1	10.7	1
185	Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS. <i>Bone Marrow Transplantation</i> , 2016 , 51, 961-6	4.4	7
184	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016 , 128, 112-112	2.2	2
183	NiCord single unit expanded umbilical cord blood transplantation: Results of phase I/II trials <i>Journal of Clinical Oncology</i> , 2016 , 34, 7004-7004	2.2	3
182	Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis. <i>Oncotarget</i> , 2016 , 7, 30492-503	3.3	30
181	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , 2016 , 7, 43027-43038	3.3	29
180	Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2016 , 97, 33-8	3.8	21
179	Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1284-1289	4.7	23
178	Advances in haploidentical stem cell transplantation for hematologic malignancies. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1766-75	1.9	9
177	Time-dependent changes in mortality and transformation risk in MDS. <i>Blood</i> , 2016 , 128, 902-10	2.2	93
176	Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2016 , 101, 1120-7	6.6	14
175	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2016 , 128, 1408-17	2.2	151
174	Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study. <i>Lancet Haematology,the</i> , 2015 , 2, e260-6	14.6	21
173	Bloodstream infections in adult patients undergoing cord blood transplantation from unrelated donors after myeloablative conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 755-60	4.7	26
172	Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment. <i>Revista Iberoamericana De Micologia</i> , 2015 , 32, 185-9	1.6	3

171	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015 , 29, 1891-900	10.7	158
170	Fluorescence in situ hybridization of TP53 for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3183-8	1.9	0
169	Risk of Rh (D) alloimmunisation after Rh (D) positive platelet transfusions in patients undergoing haematopoietic stem cell transplantation. <i>Transfusion Medicine</i> , 2015 , 25, 49-50	1.3	2
168	Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1465-72	4.4	26
167	Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. <i>Annals of Hematology</i> , 2015 , 94, 779-87	3	47
166	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. <i>Leukemia and Lymphoma</i> , 2015 , 56, 656-62	1.9	22
165	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. <i>Blood</i> , 2015 , 125, 1857-65	2.2	118
164	Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. <i>British Journal of Haematology</i> , 2015 , 170, 372-83	4.5	47
163	Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). <i>Leukemia</i> ,	10.7	76
162	2015 , 29, 1502-13 Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. <i>Leukemia</i> , 2015 , 29, 1875-81	10.7	71
161	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blooda report from Eurocord, the Acute Leukemia Working Party, and the	22.4	33
160	Cord Blood Committee of the Cellular Therapy and immunobiology Working Party of the European Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk 07 myelodysplastic syndrome and unfavorable specific lower-risk score. <i>Leukemia Research</i> , 2015 , 39, 52-7	2.7	16
159	Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT)	4.7	43
158	and Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 489-95 Effect of CD8+ cell content on umbilical cord blood transplantation in adults with hematological malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1744-50	4.7	16
157	Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2014 ,	4.4	19
156	49, 887-94 Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1841-6	4.7	40
155	Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. <i>British Journal of Haematology</i> , 2014 , 166, 189-201	4.5	12
154	Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients. <i>Leukemia Research</i> , 2014 , 38, 1199-206	2.7	6

(2013-2014)

153	Impact on Outcomes of Human Leukocyte Antigen Matching by Allele-Level Typing in Adults with Acute Myeloid Leukemia Undergoing Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 106-110	4.7	38
152	Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. <i>Leukemia Research</i> , 2014 , 38, 258-62	2.7	5
151	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). <i>Haematologica</i> , 2014 , 99, 1041-9	6.6	95
150	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. <i>Blood</i> , 2014 , 123, 133-40	2.2	199
149	Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: a single-center experience. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1084-8	4.4	26
148	Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). <i>Blood Cancer Journal</i> , 2014 , 4, e242	7	19
147	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. <i>Leukemia</i> , 2014 , 28, 779-86	10.7	81
146	EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. <i>Bone Marrow Transplantation</i> , 2014 , 49, 397-402	4.4	54
145	Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2014 , 99, 378-84	6.6	14
144	Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood	4.5	22
143	Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. <i>European Journal of Haematology</i> , 2014 , 93, 429-38	3.8	23
142	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , 2014 , 99, 1509-15	6.6	35
141	Results of treatment with azacitidine in patients aged [75 years included in the Spanish Registry of Myelodysplastic Syndromes. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1300-3	1.9	15
140	T cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1060-3	4.7	14
139	Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. <i>Leukemia Research</i> , 2014 , 38, 744-50	2.7	35
138	Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. <i>Bone Marrow Transplantation</i> , 2014 , 49, 24-9	4.4	28
137	Impact on outcomes of human leukocyte antigen matching by allele-level typing in adults with acute myeloid leukemia undergoing umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 106-10	4.7	10
136	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. <i>Leukemia Research</i> , 2013 , 37, 769-76	2.7	8

135	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 753-63	5	12
134	Myeloablative cord blood transplantation in adults with acute leukemia: comparison of two different transplant platforms. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1725-30	4.7	30
133	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. <i>Blood</i> , 2013 , 122, 2943-64	2.2	437
132	Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1387-92	4.7	20
131	Screening for IDH mutations in chronic myelomonocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 406-7	1.9	4
130	Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. <i>Journal of Clinical Oncology</i> , 2013 , 31, 916-22	2.2	60
129	Single nucleotide polymorphism array karyotyping: a diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 1167-77	5	28
128	Sequencing of a novel HLA-B allele, B*51:153, in a Spanish individual. <i>Tissue Antigens</i> , 2013 , 82, 297		3
127	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2013 , 121, 3005-15	2.2	197
126	Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. <i>Haematologica</i> , 2013 , 98, 568-75	6.6	52
125	The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. <i>Leukemia Research</i> , 2012 , 36, 287-92	2.7	16
124	Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia Research</i> , 2012 , 36, e50-1	2.7	
123	Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2012 , 91, 19-25	3	5
122	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2012 , 159, 311-21	4.5	14
121	Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival. <i>Annals of Hematology</i> , 2012 , 91, 1887-95	3	9
120	Revised international prognostic scoring system for myelodysplastic syndromes. <i>Blood</i> , 2012 , 120, 2454	1- <u>6.5</u>	1799
119	Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 100-5	4.7	17
118	Significance of increased blastic-appearing cells in bone marrow following myeloablative unrelated cord blood transplantation in adult patients. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 38	8 -9 7	6

(2010-2012)

117	Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. <i>Bone Marrow Transplantation</i> , 2012 , 47, 1287-93	4.4	112
116	Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. <i>Biology of Blood and Marrow</i>	4.7	84
115	Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. <i>Lancet Oncology, The</i> , 2011 , 12, 1214-21	21.7	174
114	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. <i>Blood</i> , 2011 , 118, 3765-76	2.2	348
113	Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. <i>Leukemia</i> , 2011 , 25, 75-81	10.7	39
112	Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. <i>Leukemia</i> , 2011 , 25, 110-20	10.7	98
111	Recommendations for management of Chagas disease in organ and hematopoietic tissue transplantation programs in nonendemic areas. <i>Transplantation Reviews</i> , 2011 , 25, 91-101	3.3	74
110	14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). <i>Leukemia Research</i> , 2011 , 35, S6	2.7	17
109	Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. <i>Cancer</i> , 2011 , 117, 2697-702	6.4	139
108	Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. <i>Cancer</i> , 2011 , 117, 5529-37	6.4	41
107	Cytogenetic risk stratification in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2011 , 96, 375-83	6.6	186
106	Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. <i>Leukemia Research</i> , 2011 , 35, 479-83	2.7	7
105	Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. <i>Leukemia Research</i> , 2011 , 35, 834-6	2.7	9
104	Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 562-9	2.2	756
103	Umbilical cord blood transplantation from unrelated donors in adult patients with chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2010 , 23, 217-22	4.2	3
102	Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 86-94	4.7	74
101	Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 957-66	4.7	28
100	Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1589-95	4.7	28

99	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. <i>Lancet Oncology, The</i> , 2010 , 11, 653-60	21.7	470
98	Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. <i>Annals of Hematology</i> , 2010 , 89, 147-54	3	25
97	Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. <i>Leukemia Research</i> , 2010 , 34, 1410-6	2.7	43
96	Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study. <i>Blood</i> , 2010 , 116, 910-910	2.2	6
95	Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. <i>Journal of Clinical Oncology</i> , 2009 , 27, 256-63	2.2	179
94	KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. <i>Leukemia</i> , 2009 , 23, 492-500	10.7	202
93	Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. <i>Leukemia</i> , 2009 , 23, 1658-66	10.7	101
92	HLA-B*0777 allele differs from B*0707 by a single residue in the antigen binding groove. <i>Tissue Antigens</i> , 2009 , 74, 543-4		5
91	Absence of mutations in the tyrosine kinase and juxtamembrane domains of C-FMS gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia Research</i> , 2009 , 33, e162-3	2.7	2
90	Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 730-40	4.7	45
89	Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. <i>Lancet Oncology, The</i> , 2009 , 10, 223-32	21.7	1961
88	Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies. <i>Haematologica</i> , 2009 , 94, 827-32	6.6	26
87	The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update. <i>Ecancermedicalscience</i> , 2008 , 2, 118	2.7	9
86	Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update. <i>Ecancermedicalscience</i> , 2008 , 2, 121	2.7	10
85	A broken cord blood bag: placing the unit in a sterile zip-lock bag before thawing prevents catastrophic events. <i>Transfusion</i> , 2008 , 48, 1282-3	2.9	2
84	Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. <i>Haematologica</i> , 2008 , 93, 67-74	6.6	148
83	Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. <i>Haematologica</i> , 2008 , 93, 1712-7	6.6	220
82	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q <i>Haematologica</i> , 2008 , 93, 1001-8	6.6	27

(2005-2008)

81	Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q-syndrome. <i>Blood</i> , 2008 , 112, 918	2.2	73
80	Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. <i>Annals of Hematology</i> , 2008 , 87, 345-52	3	64
79	Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. <i>Cancer</i> , 2008 , 113, 1351-61	6.4	386
78	Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2008 , 112, 640-640	2.2	57
77	Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2367-74	1.9	15
76	Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. <i>Bone Marrow Transplantation</i> , 2007 , 39, 555-61	4.4	79
75	Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. <i>British Journal of Haematology</i> , 2007 , 139, 70-80	4.5	99
74	A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation. <i>International Journal of Hematology</i> , 2007 , 86, 186-92	2.3	15
73	Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1488-94	1.9	54
72	Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 172-83	4.7	119
71	Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <i>Blood</i> , 2006 , 108, 419-25	2.2	1125
70	Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. <i>Bone Marrow Transplantation</i> , 2006 , 37, 33-40	4.4	40
69	The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. <i>Leukemia</i> , 2006 , 20, 1319-21	10.7	80
68	The JAK2 V617F mutation is rare in RARS but common in RARS-T. <i>Leukemia</i> , 2006 , 20, 2060-1	10.7	67
67	Unrelated cord blood transplants in adults with hematologic malignancies. <i>Haematologica</i> , 2006 , 91, 223-30	6.6	81
66	Unrelated donor umbilical cord blood transplantation in adults with hematologic malignancies. <i>Pathologie Et Biologie</i> , 2005 , 53, 165-6		3
65	SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. <i>British Journal of Haematology</i> , 2005 , 129, 791-4	4.5	19
64	Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Espaöl de Trasplante HemopoyEico). <i>Bone Marrow Transplantation</i> , 2005 , 36, 301-6	4.4	7

63	Transplantation of CD34+ selected peripheral blood to HLA-identical sibling patients with aplastic anaemia: results from a single institution. <i>Bone Marrow Transplantation</i> , 2005 , 36, 325-9	4.4	8
62	Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clinical Cancer Research, 2005,	12.9	113
61	Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. <i>Haematologica</i> , 2005 , 90, 1168-78	6.6	147
60	Unrelated-donor cord blood transplantation for adult hematological malignancies. <i>Leukemia and Lymphoma</i> , 2004 , 45, 11-8	1.9	11
59	Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. <i>New England Journal of Medicine</i> , 2004 , 351, 2276-85	59.2	956
58	CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. <i>Clinical Cancer Research</i> , 2004 , 10, 7599-606	12.9	27
57	Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. <i>Leukemia</i> , 2004 , 18, 1031-4	10.7	1
56	Expression of APO2.7, bcl-2 and bax apoptosis-associated proteins in CD34- bone marrow cell compartments from patients with myelodysplastic syndromes. <i>Leukemia</i> , 2004 , 18, 1311-3	10.7	7
55	Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation. <i>Leukemia</i> , 2004 , 18, 1165-7	10.7	1
54	Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. <i>Experimental Hematology</i> , 2004 , 32, 397-407	3.1	342
53	Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission. <i>International Journal of Hematology</i> , 2004 , 80, 168-73	2.3	0
52	Hla-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease. <i>Transplantation</i> , 2004 , 77, 1107-10	1.8	22
51	Umbilical cord blood transplantation. Current Opinion in Hematology, 2004, 11, 375-85	3.3	60
50	Allogeneic Transplant in Patients with Poor Prognosis B-Chronic Lymphocytic Leukemia (B-CLL): Comparative Study between Myeloablative(M) and Non-Myeloablative(NM) Conditioning Regimen <i>Blood</i> , 2004 , 104, 2306-2306	2.2	1
49	Umbilical cord blood transplantation: current status and future directions. <i>Current Opinion in Organ Transplantation</i> , 2003 , 8, 109-117	2.5	3
48	Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2003 , 31, 545-50	3.1	28
47	Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. <i>Leukemia Research</i> , 2003 , 27, 5-12	2.7	38
46	Peripheral blood is safer than bone marrow as a source of hematopoietic progenitors in patients with myelodysplastic syndromes who receive an allogeneic transplantation. Results from the Spanish registry. <i>Bone Marrow Transplantation</i> 2003 32, 987-92	4.4	23

(2000-2002)

45	Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. <i>British Journal of Haematology</i> , 2002 , 116, 475-82	4.5	175
44	Infectious complications in patients undergoing unrelated donor bone marrow transplantation: experience from a single institution. <i>Clinical Microbiology and Infection</i> , 2002 , 8, 725-33	9.5	26
43	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. <i>Leukemia Research</i> , 2002 , 26, 725-30	2.7	38
42	Early infections in adult patients undergoing unrelated donor cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2002 , 30, 937-43	4.4	87
41	Unrelated donor umbilical cord blood transplantation in adults. <i>Leukemia</i> , 2002 , 16, 1984-91	10.7	42
40	Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies. <i>Bone Marrow Transplantation</i> , 2002 , 29, 825-32	4.4	32
39	Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. <i>Blood</i> , 2002 , 100, 2243-5	2.2	152
38	Myelodysplastic syndromes standardized response criteria: further definition. <i>Blood</i> , 2001 , 98, 1985	2.2	30
37	Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. <i>Blood</i> , 2001 , 98, 2332-8	2.2	202
36	Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor	4.5	60
35	Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2001 , 115, 1002-3	4.5	100
34	Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?. <i>Transfusion</i> , 2001 , 41, 106-10	2.9	33
33	Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 27, 21-5	4.4	22
32	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. <i>Leukemia Research</i> , 2001 , 25, 685-92	2.7	10
31	Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. <i>Bone Marrow Transplantation</i> , 2001 , 27, 693-701	4.4	35
30	Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. <i>Bone Marrow Transplantation</i> , 2001 , 27, 983-8	3 ^{4·4}	25
29	Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3447-52	2.2	56
28	Graft-versus-tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2000 , 111, 708-10	4.5	25

27	Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Espaöl de Trasplante HemopoyEico. <i>Haematologica</i> , 2000 , 85, 530-8	6.6	5
26	Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. <i>BJU International</i> , 1999 , 84, 1028-31	5.6	73
25	Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 1999 , 24, 389-96	4.4	36
24	Liver disease as primary manifestation of multiple myeloma in a young man. <i>Leukemia Research</i> , 1999 , 23, 403-5	2.7	12
23	Chronic myeloid leukemia with expression of ALL-type BCR/ABL transcript: a case-report and review of the literature. <i>Leukemia Research</i> , 1999 , 23, 851-4	2.7	9
22	Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT. <i>Bone Marrow Transplantation</i> , 1998 , 22, 519-25	4.4	49
21	International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes. <i>Blood</i> , 1997 , 89, 2079-2088	2.2	3508
20	Etiopathogeny, prognosis and therapy of myelodysplastic syndromes. <i>Hematology and Cell Therapy</i> , 1997 , 39, 277-94		12
19	International scoring system for evaluating prognosis in myelodysplastic syndromes. <i>Blood</i> , 1997 , 89, 2079-88	2.2	1112
18	Myelodysplastic syndromes. <i>Critical Reviews in Oncology/Hematology</i> , 1996 , 23, 57-93	7	14
17	Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases. <i>Leukemia and Lymphoma</i> , 1993 , 12, 103-8	1.9	21
16	Feasibility of early discharge after acute Q wave myocardial infarction in patients not receiving thrombolytic treatment. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 1795-801	15.1	21
15	Prognostic factors in myelodysplastic syndromes. <i>Leukemia Research</i> , 1992 , 16, 77-86	2.7	45
14	PROGNOSTIC IRRELEVANCE OF CD34 IN ACUTE MYELOID LEUKAEMIA. <i>British Journal of Haematology</i> , 1992 , 82, 480-480	4.5	
13	Prognostic value of CD34 expression in de novo acute myeloblastic leukaemia. <i>British Journal of Haematology</i> , 1991 , 79, 533-4	4.5	29
12	Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. <i>British Journal of Haematology</i> , 1990 , 75, 26-33	4.5	66
11	Two types of acquired idiopathic sideroblastic anaemia. <i>British Journal of Haematology</i> , 1990 , 75, 633-4	4.5	8
10	Acute Promyelocytic Leukaemia. Relationship of Cytochemical Pattern with Clinical, Morphologic and Immunological Characteristics, and Outcome. <i>Leukemia and Lymphoma</i> , 1990 , 2, 85-92	1.9	2

LIST OF PUBLICATIONS

9	Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Espaßl para el Seguimiento del Injerto Coronario (GESIC). <i>Circulation</i> , 1990 , 82, 765-73	16.7	91	
8	Chronic myelomonocytic leukemiaclinicobiological characteristics: a multivariate analysis in a series of 70 cases. <i>European Journal of Haematology</i> , 1989 , 42, 466-73	3.8	21	
7	Validation of survival-predictive models in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 1989 , 30, 44	7.1		
6	Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. <i>American Journal of Hematology</i> , 1988 , 27, 163-8	7.1	37	
5	Essential thrombocythemia and pregnancy. American Journal of Hematology, 1988, 28, 66	7.1	8	
4	Acute promyelocytic leukemia. Therapy results and prognostic factors. <i>Cancer</i> , 1988 , 61, 7-13	6.4	106	
3	Predictors of non-fatal ischemic events after myocardial infarction. <i>International Journal of Cardiology</i> , 1988 , 20, 73-86	3.2	14	
2	Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. <i>New England Journal of Medicine</i> , 1982 , 306, 1065-70	59.2	489	
1	Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes		2	